Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia

Neurology

Volumn 61, Issue 12, 2003, Pages 1673-1679

  Haier, R J ^a,b   Alkire, M T ^b   White, N S ^a   Uncapher, M R ^a   Head, E ^b   Lott, I T ^a   Cotman, C W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BRAIN METABOLISM; CLINICAL ARTICLE; DEMENTIA; DOWN SYNDROME; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERMETABOLISM; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEMPORAL CORTEX;

EID: 0347994923     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000098935.36984.25     Document Type: Article

References (41)

1. Oliver C, Holland AJ. Down's syndrome and Alzheimer's disease: a review. Psychol Med 1986;16:307-322.
2. Lott IT, Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev 2001;7:172-178.
3. Wisniewski KE, Dalton AJ, McLachlan C, Wen GY, Wisniewski HM. Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology 1985;35:957-961.
4. Devenny DA, Silverman WP, Hill AL, et al. Normal ageing in adults with Down's syndrome: a longitudinal study. J Intellect Disabil Res 1996;40:208-221.
5. Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989;46:849-853.
6. Zigman WB, Schupf N, Sersen E, Silverman W. Prevalence of dementia in adults with and without Down syndrome. Am J Ment Retard 1996;100:403-412.
7. Huxley A, Prasher VP, Haque MS. The Dementia Scale for Down's syndrome. J Intellect Disabil Res 2000;44:697-708.
8. Evenhuis HM. Further evaluation of the Dementia Questionnaire for Persons with Mental Retardation (DMR). J Intellect Disabil Res 1996;40:369-373.
9. Deb S, Braganza J. Comparison of rating scales for the diagnosis of dementia in adults with Down's syndrome. J Intellect Disabil Res 1999;43:400-407.
10. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Firth CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Map 1995;2:189-210.
11. Price CJ, Friston KJ. Cognitive conjunction: a new approach to brain activation experiments. Neuroimage 1997;5:261-270.
12. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain: a 3-dimensional proportional system, an approach to cerebral imaging. Stuttgart: G. Thieme, 1988.
13. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-357.
14. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120-2127.
15. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002;159:738-745.
16. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
17. Herholz K, Nordberg A, Salmon E, et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord 1999;10:494-504.
18. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98:10966-10971.
19. Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:6037-6042.
20. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752-758.
21. Reiman EM, Caselli RJ, Chen K, et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:3334-3339.
22. Fox NC, Crum WR, Scahill RI, et al. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001;358:201-205.
23. Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA 2002;99:4703-4707.
24. Smith AD. Imaging the progression of Alzheimer pathology through the brain. Proc Natl Acad Sci USA 2002;99:4135-4137.
25. Minoshima S, Cross DJ, Foster NL, Henry TR, Kuhl DE. Discordance between traditional pathologic and energy metabolic changes in very early Alzheimer's disease. Pathophysiological implications. Ann NY Acad Sci 1999;893:350-352.
26. Dani A, Pietrini P, Furey ML, et al. Brain cognition and metabolism in Down syndrome adults in association with development of dementia. Neuroreport 1996;7:2933-2936.
27. Pietrini P, Dani A, Furey ML, et al. Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Am J Psychiatry 1997;154:1063-1069.
28. Haier RJ, Chueh D, Touchette P, et al. Brain size and cerebral glucose metabolic rate in nonspecific mental retardation and Down syndrome. Intelligence 1995;20:191-210.
29. Cutler NR. Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndrome. Prog Neuropsychopharmacol Biol Psychiatry 1986;10:309-321.
30. Schwartz M, Duara R, Haxby J, et al. Down's syndrome in adults: brain metabolism. Science 1983;221:781-783.
31. Balogh E, Lengyel Z, Emri M, et al. [Cerebral glucose metabolism in Down syndrome using positron emission tomography]. Orv Hetil 2002;143:1304-1307.
32. Schapiro MB, Grady CL, Kumar A, et al. Regional cerebral glucose metabolism is normal in young adults with Down syndrome. J Cereb Blood Flow Metab 1990;10:199-206.
33. Labudova O, Cairns N, Kitzmuller E, Lubec G. Impaired brain glucose metabolism in patients with Down syndrome. J Neural Transm [Suppl] 1999;57:247-256.
34. Lubec G, Labudova O, Cairns N, Fountoulakis M. Increased glyceraldehyde 3-phosphate dehydrogenase levels in the brain of patients with Down's syndrome. Neurosci Lett 1999;260:141-145.
35. Peled-Kamar M, Degani H, Bendel P, Margalit R, Groner Y. Altered brain glucose metabolism in transgenic-PFKL mice with elevated L-phosphofructokinase: in vivo NMR studies. Brain Res 1998;810:138-145.
36. Haier RJ, Siegel BV, Nuechterlein KH, et al. Cortical glucose metabolic rate correlates of abstract reasoning and attention studied with positron emission tomography. Intelligence 1988;12:199-217.
37. Mesulam MM. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 1999;24:521-529.
38. Head E, Lott IT, Hof PR, et al. Age-dependent hippocampal Tau phosphorylation in individuals with Down syndrome: evidence for parallel compensatory and pathological events. J Neuropathol Exp Neurol 2003;62:917-926.
39. White NB, Alkire MT, Haier RJ. A voxel-based morphometric study of non-demented adults with Down syndrome. Neuroimage 2003;20:393-403.
40. Grady CL, McIntosh AR, Beig S, et al. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J Neurosci 2003;23:986-993.
41. Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000;343:450-456.